Brief: Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
10/11/2023 13:12
Nov 10 (Reuters) - Pacira Biosciences Inc PCRX.O :
* PACIRA ANNOUNCES FDA APPROVAL OF EXPANDED EXPAREL LABEL TO
INCLUDE TWO ADDITIONAL NERVE BLOCK INDICATIONS
* PACIRA BIOSCIENCES INC: NEW INDICATIONS FOR USE AS AN
ADDUCTOR
CANAL BLOCK AND SCIATIC NERVE BLOCK IN POPLITEAL FOSSA
* PACIRA BIOSCIENCES INC: EXPAREL ACHIEVED STATISTICAL
SIGNIFICANCE FOR STUDIES' SECONDARY ENDPOINT OF REDUCED
POSTSURGICAL OPIOID CONSUMPTION
Source text for Eikon: ID:nGNX53QSGv
Further company coverage: PCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees